Pharmacovigilance Assessment of Drug-Induced Acute Pancreatitis Using a Spontaneous Reporting Database. (November 2019)

• Record Type: Journal Article
• Authors: Niinomi, Iku; Hosohata, Keiko; Oyama, Saki; Inada, Ayaka; Wakabayashi, Tomohito; Iwanaga, Kazunori
• Is Part Of: International journal of toxicology. Volume 38:Number 6(2019)
• Page Start: 487
• Page End: 492
• Publication Date: 2019-11
• Subjects: acute pancreatitis -- drug-induced adverse events -- spontaneous reporting system -- reporting odds ratio (ROR) -- Japanese Adverse Drug Event Report (JADER) database; Toxicology -- Periodicals; 615.9005
• DOI: 10.1177/1091581819870717
• Languages: English
• ISSNs: 1091-5818

Abstract

Background: Acute pancreatitis (AP) is associated with risks of morbidity and mortality. The incidence of AP recently increased compared to that traditionally reported in the literature. Objective: The purpose of this study was to evaluate the possible association between AP and drugs using the Japanese Adverse Drug Event Report (JADER) database, which is a spontaneous reporting database of adverse drug events. Methods: Adverse event reports submitted to the JADER database between 2004 and 2017 were analyzed. Disproportionality analysis was performed by calculating the reporting odds ratio (ROR) with 95% confidence intervals for signal detection. Results: A total of 3, 443 reports (0.17% of all adverse events) were identified as drug-induced AP, in which 431 different drugs were involved. Acute pancreatitis was frequently reported in men (58.5%) in their 60s (19.1%); 40.6% developed AP within 4 weeks after the treatment. Among the most frequently reported drugs, signals were detected for prednisolone, ribavirin, sitagliptin, mesalazine, tacrolimus, andl -asparaginase, which are well-known causes of AP. Telaprevir, donepezil, and ustekinumab also generated signals. As for drugs with high RORs, l -asparaginase and alogliptin were noteworthy. Conclusion: Most of the identified drugs were already known to induce AP, but the likelihood of the reporting of AP varied among the drugs. Our results should raise physicians' awareness of drugs associated with AP, but further investigation of these medications is warranted.